{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:38:58Z","timestamp":1787895538543,"version":"build-2784847793"},"reference-count":93,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccines constitute a pillar in the prevention of infectious diseases. The unprecedented emergence of novel immunization strategies due to the COVID-19 pandemic has again positioned vaccination as a pivotal measure to protect humankind and reduce the clinical impact and socioeconomic burden worldwide. Vaccination pursues the ultimate goal of eliciting a protective response in immunized individuals. To achieve this, immunogens must be efficiently delivered to prime the immune system and produce robust protection. Given their safety, immunogenicity, and flexibility to display varied and native epitopes, self-assembling protein nanoparticles represent one of the most promising immunogen delivery platforms. Currently marketed vaccines against the human papillomavirus, for instance, illustrate the potential of these nanoassemblies. This review is intended to provide novelties, since 2015, on the ground of vaccine design and self-assembling protein nanoparticles, as well as a comparison with the current emergence of mRNA-based vaccines.<\/jats:p>","DOI":"10.3390\/vaccines10091447","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T20:50:27Z","timestamp":1662670227000},"page":"1447","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Self-Assembling Protein Nanoparticles in the Design of Vaccines: 2022 Update"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3392-693X","authenticated-orcid":false,"given":"Sergio","family":"Morales-Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Unit of Protein Crystallography and Structural Immunology, Navarrabiomed-Public University of Navarra (UPNA), 31008 Pamplona, Spain"},{"name":"Navarra University Hospital, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Ugidos-Damboriena","sequence":"additional","affiliation":[{"name":"Unit of Protein Crystallography and Structural Immunology, Navarrabiomed-Public University of Navarra (UPNA), 31008 Pamplona, Spain"},{"name":"Navarra University Hospital, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-4361","authenticated-orcid":false,"given":"Jacinto","family":"L\u00f3pez-Sagaseta","sequence":"additional","affiliation":[{"name":"Unit of Protein Crystallography and Structural Immunology, Navarrabiomed-Public University of Navarra (UPNA), 31008 Pamplona, Spain"},{"name":"Navarra University Hospital, 31008 Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of Vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.antiviral.2009.08.008","article-title":"Wanted, Dead or Alive: New Viral Vaccines","volume":"84","author":"Amanna","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine Manufacturing: Challenges and Solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"ref_4","first-page":"174","article-title":"Production of Virus-like Particles for Vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/infdis\/jiu648","article-title":"Raising Expectations For Subunit Vaccine","volume":"211","author":"Schiller","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"118919","DOI":"10.1016\/j.lfs.2020.118919","article-title":"DNA Vaccines against COVID-19: Perspectives and Challenges","volume":"267","author":"Silveira","year":"2021","journal-title":"Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fimmu.2014.00030","article-title":"On the Role of Dendritic Cells versus Other Cells in Inducing Protective CD8+ T Cell Responses","volume":"5","author":"Zinkernagel","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like Particles as a Highly Efficient Vaccine Platform: Diversity of Targets and Production Systems and Advances in Clinical Development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-Assembling Protein Nanoparticles in the Design of Vaccines","volume":"14","author":"Malito","year":"2016","journal-title":"CSBJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like Particles: Preparation, Immunogenicity and Their Roles as Nanovaccines and Drug Nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18388\/abp.2014_1875","article-title":"Virus-like Particles as Vaccine","volume":"61","author":"Chroboczek","year":"2014","journal-title":"Acta Biochim. Pol."},{"key":"ref_13","first-page":"891","article-title":"Human Papillomavirus Type16-L1 VLP Production in Insect Cells","volume":"16","author":"Abdoli","year":"2013","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/bit.25159","article-title":"Bioengineering Virus-like Particles as Vaccines","volume":"111","author":"Lua","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like Particle Vaccines: Immunology and Formulation for Clinical Translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1128\/JVI.00449-16","article-title":"Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1\/L2 Chimeric Virus-Like Particles","volume":"90","author":"Boxus","year":"2016","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"63333","DOI":"10.18632\/oncotarget.19327","article-title":"Human Papillomavirus 16L1-58L2 Chimeric Virus-like Particles Elicit Durable Neutralizing Antibody Responses against a Broad-Spectrum of Human Papillomavirus Types","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4014\/jmb.1511.11010","article-title":"High-Level Production of Human Papillomavirus (HPV) Type 16 L1 in Escherichia Coli","volume":"26","author":"Bang","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virusres.2016.04.017","article-title":"Human Papillomavirus L1 Protein Expressed in Escherichia coli Self-Assembles into Virus-like Particles That Are Highly Immunogenic","volume":"220","author":"Chen","year":"2016","journal-title":"Virus Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1016\/j.vaccine.2019.09.072","article-title":"Combination of Three Virus-Derived Nanoparticles as a Vaccine against Enteric Pathogens; Enterovirus, Norovirus and Rotavirus","volume":"37","author":"Hankaniemi","year":"2019","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-020-00260-w","article-title":"Disulfide Stabilization of Human Norovirus GI.1 Virus-like Particles Focuses Immune Response toward Blockade Epitopes","volume":"5","author":"Verardi","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12934-021-01677-1","article-title":"Immunization with Leishmania Tarentolae-Derived Norovirus Virus-like Particles Elicits High Humoral Response and Stimulates the Production of Neutralizing Antibodies","volume":"20","author":"Panasiuk","year":"2021","journal-title":"Microb. Cell Factories"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tan, M., and Jiang, X. (2019). Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11090472"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.vaccine.2017.03.065","article-title":"A Novel Combined Vaccine Based on Monochimeric VLP Co-Displaying Multiple Conserved Epitopes against Enterovirus 71 and Varicella-Zoster Virus","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Son, H.S., Lee, S.W., Yoon, Y., Hyeon, J.Y., Chung, G.T., Lee, J.W., and Yoo, J.S. (2019). Efficient Expression of Enterovirus 71 Based on Virus-like Particles Vaccine. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210477"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1080\/21645515.2019.1649554","article-title":"Development and Characterization of an Enterovirus 71 (EV71) Virus-like Particles (VLPs) Vaccine Produced in Pichia Pastoris","volume":"16","author":"Yang","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.vaccine.2021.06.031","article-title":"Preclinical Evaluation of Recombinant HFMD Vaccine Based on Enterovirus 71 (EV71) Virus-like Particles (VLP): Immunogenicity, Efficacy and Toxicology","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.18632\/oncotarget.8475","article-title":"MERS-CoV Virus-like Particles Produced in Insect Cells Induce Specific Humoural and Cellular Imminity in Rhesus Macaques","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Naskalska, A., Dabrowska, A., Nowak, P., Szczepanski, A., Jasik, K., Milewska, A., Ochman, M., Zeglen, S., Rajfur, Z., and Pyrc, K. (2018). Novel Coronavirus-like Particles Targeting Cells Lining the Respiratory Tract. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203489"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","article-title":"Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/all.15091","article-title":"Development and Preclinical Evaluation of Virus-like Particle Vaccine against COVID-19 Infection","volume":"77","author":"Yilmaz","year":"2022","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/all.15080","article-title":"A Scalable and Highly Immunogenic Virus-like Particle-Based Vaccine against SARS-CoV-2","volume":"77","author":"Mohsen","year":"2022","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"eabq0839","DOI":"10.1126\/science.abq0839","article-title":"Mosaic RBD Nanoparticles Protect against Challenge by Diverse Sarbecoviruses in Animal Models","volume":"377","author":"Cohen","year":"2022","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"19255","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr Virus-like Particles Incorporating GH\/GLEBNA1 or GB-LMP2 Induce High Neutralizing Antibody Titers and EBV-Specific T-Cell Responses in Immunized Mice","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Atcheson, E., Bauza, K., Salman, A.M., Alves, E., Blight, J., Viveros-Sandoval, M.E., Janse, C.J., Khan, S.M., Hill, A.V.S., and Reyes-Sandoval, A. (2018). Tailoring a Plasmodium Vivax Vaccine to Enhance Efficacy through a Combination of a CSP Virus-like Particle and TRAP Viral Vectors. Infect. Immun., 86.","DOI":"10.1128\/IAI.00114-18"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.vaccine.2019.01.056","article-title":"Hepatitis B Virus-like Particles Expressing Plasmodium Falciparum Epitopes Induce Complement-Fixing Antibodies against the Circumsporozoite Protein","volume":"37","author":"Kingston","year":"2019","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cec\u00edlio, P., P\u00e9rez-Cabezas, B., Fern\u00e1ndez, L., Moreno, J., Carrillo, E., Requena, J.M., Fichera, E., Reed, S.G., Coler, R.N., and Kamhawi, S. (2017). Pre-Clinical Antigenicity Studies of an Innovative Multivalent Vaccine for Human Visceral Leishmaniasis. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005951"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Joyner, J.A., Daly, S.M., Peabody, J., Triplett, K.D., Pokhrel, S., Elmore, B.O., Adebanjo, D., Peabody, D.S., Chackerian, B., and Hall, P.R. (2020). Vaccination with VLPs Presenting a Linear Neutralizing Domain of S. Aureus Hla Elicits Protective Immunity. Toxins, 12.","DOI":"10.3390\/toxins12070450"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2217\/17460794.3.1.83","article-title":"Host-Range and Pathogenicity of Hepatitis B Viruses","volume":"3","author":"Netter","year":"2008","journal-title":"Futur. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1002\/1521-4141(200211)32:11<3305::AID-IMMU3305>3.0.CO;2-J","article-title":"Regulation of IgG Antibody Responses by Epitope Density and CD21-Mediated Costimulation","volume":"32","author":"Jegerlehner","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.copbio.2013.11.005","article-title":"Pathogen-like Particles: Biomimetic Vaccine Carriers Engineered at the Nanoscale","volume":"28","author":"Rosenthal","year":"2014","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The Biology and Life-Cycle of Human Papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a Bivalent L1 Virus-like Particle Vaccine in Prevention of Infection with Human Papillomavirus Types 16 and 18 in Young Women: A Randomised Controlled Trial","volume":"364","author":"Biologicals","year":"2004","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the Immunogenicity and Safety of CervarixTM and Gardasil\u00ae Human Papillomavirus (HPV) Cervical Cancer Vaccines in Healthy Women Aged 18-45 Years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccin."},{"key":"ref_47","first-page":"300","article-title":"Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(14)70767-4","article-title":"Global Prevalence of Norovirus in Cases of Gastroenteritis: A Systematic Review and Meta-Analysis","volume":"14","author":"Ahmed","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1086\/314783","article-title":"Identification of a Distinct Common Strain of \u201cNorwalk-like Viruses\u201d Having a Global Distribution","volume":"179","author":"Noel","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0213-005X(10)70009-4","article-title":"Infecciones Por Norovirus","volume":"28","year":"2010","journal-title":"Enferm. Infecc. Microbiol. Cl\u00edn."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.femsle.2005.08.031","article-title":"Norovirus Protein Structure and Function","volume":"253","author":"Hardy","year":"2005","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1016\/j.vaccine.2017.06.043","article-title":"Norovirus Vaccines under Development","volume":"36","author":"Lucero","year":"2018","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8048","DOI":"10.1073\/pnas.0600421103","article-title":"X-ray Structure of a Native Calicivirus: Structural Insights into Antigenic Diversity and Host Specificity","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2008.08.047","article-title":"Noroviral P Particle: Structure, Function and Applications in Virus-Host Interaction","volume":"382","author":"Tan","year":"2008","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Xia, M., Huang, P., Jiang, X., and Tan, M. (2021). A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan. Viruses, 13.","DOI":"10.3390\/v13010072"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acsnano.8b02776","article-title":"Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform","volume":"12","author":"Xia","year":"2018","journal-title":"ACS Nano."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Xia, M., Huang, P., and Tan, M. (2022). A Pseudovirus Nanoparticle-Based Trivalent Rotavirus Vaccine Candidate Elicits High and Cross P Type Immune Response. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081597"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.4161\/hv.28626","article-title":"Vaccine against Norovirus","volume":"10","author":"Tan","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/jmv.26474","article-title":"The Endemic GII. 4 Norovirus-like-Particle Induced-Antibody Lacks of Cross-Reactivity against the Epidemic GII. 17 Strain","volume":"93","author":"Du","year":"2021","journal-title":"J. Med Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2012.03.050","article-title":"Immunogenicity and Specificity of Norovirus Consensus GII.4 Virus-like Particles in Monovalent and Bivalent Vaccine Formulations","volume":"30","author":"Parra","year":"2012","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ramani, S., Neill, F.H., Ferreira, J., Treanor, J.J., Frey, S.E., Topham, D.J., Goodwin, R.R., Borkowski, A., Baehner, F., and Mendelman, P.M. (2017). B-Cell Responses to Intramuscular Administration of a Bivalent Virus-like Particle Human Norovirus Vaccine. Clin. Vaccine Immunol., 24.","DOI":"10.1128\/CVI.00571-16"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3201\/eid1611.100104","article-title":"Enterovirus 71 Infection with Central Nervous System Involvement, South Korea","volume":"16","author":"Ryu","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Haaheim, L.R., Pattison, J.R., and Whitley, R.J. (2002). A Practical Guide to Clinical Virology, Wiley.","DOI":"10.1002\/0470857285"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Liu, W., Wu, S., Xiong, Y., Li, T., Wen, Z., Yan, M., Qin, K., Liu, Y., and Wu, J. (2014). Co-Circulation and Genomic Recombination of Coxsackievirus A16 and Enterovirus 71 during a Large Outbreak of Hand, Foot, and Mouth Disease in Central China. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096051"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0168-1702(95)00087-9","article-title":"Complete Nucleotide Sequence of Enterovirus 71 Is Distinct from Poliovirus","volume":"39","author":"Brown","year":"1995","journal-title":"Virus Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102487","DOI":"10.1016\/j.jaut.2020.102487","article-title":"The Deadly Coronaviruses: The 2003 SARS Pandemic and the 2020 Novel Coronavirus Epidemic in China, the Company\u2019 s Public News and Information","volume":"109","author":"Yang","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbrc.2004.04.111","article-title":"Assembly of Human Severe Acute Respiratory Syndrome Coronavirus-like Particles","volume":"318","author":"Ho","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-00376-4","article-title":"Targeting the Signaling in Epstein\u2013Barr Virus-Associated Diseases: Mechanism, Regulation, and Clinical Study","volume":"6","author":"Cao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gething, P.W., Elyazar, I.R.F., Moyes, C.L., Smith, D.L., Battle, K.E., Guerra, C.A., Patil, A.P., Tatem, A.J., Howes, R.E., and Myers, M.F. (2012). A Long Neglected World Malaria Map: Plasmodium Vivax Endemicity in 2010. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001814"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10739-010-9239-3","article-title":"Malaria: Origin of the Term \u201cHypnozoite\u201d","volume":"44","author":"Markus","year":"2011","journal-title":"J. Hist. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"h4067","DOI":"10.1136\/bmj.h4067","article-title":"European Medicines Agency Approves First Malaria Vaccine","volume":"351","author":"Hawkes","year":"2015","journal-title":"BMJ"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"srep46482","DOI":"10.1038\/srep46482","article-title":"Rational Development of a Protective P. Vivax Vaccine Evaluated with Transgenic Rodent Parasite Challenge Models","volume":"7","author":"Salman","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: Complexity at the Host-Pathogen Interface","volume":"9","author":"Kaye","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Alvar, J., V\u00e9lez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., and de Boer, M. (2012). Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035671"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.meegid.2014.07.028","article-title":"What\u2019s behind a Sand Fly Bite? The Profound Effect of Sand Fly Saliva on Host Hemostasis, Inflammation and Immunity","volume":"28","author":"Abdeladhim","year":"2014","journal-title":"Infect. Genet. Evol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus Aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/21505594.2021.1878688","article-title":"Pathogenicity and Virulence of Staphylococcus Aureus","volume":"12","author":"Cheung","year":"2021","journal-title":"Virulence"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Oscherwitz, J., and Cease, K.B. (2015). Identification and Validation of a Linear Protective Neutralizing Epitope in the \u03b2-Pore Domain of Alpha Toxin. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116882"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 Vaccines for Their Characteristics, Efficacy and Effectiveness against SARS-CoV-2 and Variants of Concern: A Narrative Review","volume":"28","author":"Fiolet","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A Guide to Vaccinology: From Basic Principles to New Developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4049\/jimmunol.0901540","article-title":"Cutting Edge: Limited Specialization of Dendritic Cell Subsets for MHC Class II-Associated Presentation of Viral Particles","volume":"184","author":"Keller","year":"2010","journal-title":"J. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/JVI.01689-07","article-title":"Identification of Hexon-Specific CD4 and CD8 T-Cell Epitopes for Vaccine and Immunotherapy","volume":"82","author":"Leen","year":"2008","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"MRNA Vaccines-a New Era in Vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and Efficacy of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0734-9750(97)88677-6","article-title":"Adenovirus Vectors for Gene Therapy","volume":"15","author":"Wilson","year":"1997","journal-title":"Biotechnol. Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2021.08.052","article-title":"Safety and Immunogenicity of a Plant-Derived Rotavirus-like Particle Vaccine in Adults, Toddlers and Infants","volume":"39","author":"Kurokawa","year":"2021","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.vaccine.2021.01.004","article-title":"Phase III: Randomized Observer-Blind Trial to Evaluate Lot-to-Lot Consistency of a New Plant-Derived Quadrivalent Virus like Particle Influenza Vaccine in Adults 18\u201349 Years of Age","volume":"39","author":"Ward","year":"2021","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41423-021-00809-2","article-title":"Safety, Immunogenicity, and Protection Provided by Unadjuvanted and Adjuvanted Formulations of a Recombinant Plant-Derived Virus-like Particle Vaccine Candidate for COVID-19 in Nonhuman Primates","volume":"19","author":"Pillet","year":"2022","journal-title":"Cell Mol. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.1038\/s41598-017-08247-9","article-title":"Virus-like Particles That Display Zika Virus Envelope Protein Domain III Induce Potent Neutralizing Immune Responses in Mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1447\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:13Z","timestamp":1760142133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/9\/1447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":93,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["vaccines10091447"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10091447","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}